标题
Primary myelofibrosis: 2021 update on diagnosis, risk‐stratification and management
作者
关键词
-
出版物
AMERICAN JOURNAL OF HEMATOLOGY
Volume 96, Issue 1, Pages 145-162
出版商
Wiley
发表日期
2020-11-17
DOI
10.1002/ajh.26050
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure
- (2020) Claire N. Harrison et al. AMERICAN JOURNAL OF HEMATOLOGY
- A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis
- (2020) Kristen Pettit et al. BLOOD
- Myelofibrosis biology and contemporary management
- (2020) Naseema Gangat et al. BRITISH JOURNAL OF HAEMATOLOGY
- RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features
- (2020) Giacomo Coltro et al. Blood Advances
- Impact Of Spleen Size And Splenectomy On Outcomes Of Allogeneic Haematopoietic Cell Transplantation For Myelofibrosis: A Retrospective Analysis By The Chronic Malignancies Working Party On Behalf Of Ebmt.
- (2020) Nicola Polverelli et al. AMERICAN JOURNAL OF HEMATOLOGY
- Venetoclax plus hypomethylating agent in blast‐phase myeloproliferative neoplasm: preliminary experience with 12 patients
- (2020) Naseema Gangat et al. BRITISH JOURNAL OF HAEMATOLOGY
- ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial
- (2020) Stephen T. Oh et al. Blood Advances
- Splenectomy before allogeneic hematopoietic cell transplantation for myelofibrosis: A French nationwide study
- (2020) Jean‐Baptiste Bossard et al. AMERICAN JOURNAL OF HEMATOLOGY
- Splenic irradiation before allogeneic stem cell transplantation for myelofibrosis
- (2019) Grzegorz Helbig et al. MEDICAL ONCOLOGY
- Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model
- (2019) Rangit R. Vallapureddy et al. Blood Cancer Journal
- Aurora kinase A inhibition provides clinical benefit, normalizes megakaryocytes and reduces bone marrow fibrosis in patients with myelofibrosis
- (2019) Naseema Gangat et al. CLINICAL CANCER RESEARCH
- Results from HARMONY: an open-label, multicentre, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis
- (2019) Simon T. Durrant et al. HAEMATOLOGICA
- Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
- (2019) Donal McLornan et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Prognostic impact of RAS-pathway mutations in patients with myelofibrosis
- (2019) Fabio P. S. Santos et al. LEUKEMIA
- Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis
- (2018) Ayalew Tefferi et al. AMERICAN JOURNAL OF HEMATOLOGY
- Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: A second experience
- (2018) Inuk Zandvakili et al. AMERICAN JOURNAL OF HEMATOLOGY
- Early thrombotic events and preemptive systemic anticoagulation following splenectomy for myelofibrosis
- (2018) Mythri Mudireddy et al. AMERICAN JOURNAL OF HEMATOLOGY
- Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant Outcomes
- (2018) Bethany T. Samuelson Bannow et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease
- (2018) Hanna Jean Khoury et al. BONE MARROW TRANSPLANTATION
- Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis
- (2018) Sharifah Shahnaz Syed Abd Kadir et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Fatal Disseminated Tuberculosis during Treatment with Ruxolitinib Plus Prednisolone in a Patient with Primary Myelofibrosis: A Case Report and Review of the Literature
- (2018) Yasuhiro Tsukamoto et al. INTERNAL MEDICINE
- MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis
- (2018) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis
- (2018) Paola Guglielmelli et al. JOURNAL OF CLINICAL ONCOLOGY
- Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients
- (2018) Maura Nicolosi et al. LEUKEMIA
- Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients
- (2018) Ayalew Tefferi et al. LEUKEMIA
- U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions
- (2018) Ayalew Tefferi et al. LEUKEMIA
- Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts
- (2018) Ayalew Tefferi et al. LEUKEMIA
- GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis
- (2018) Ayalew Tefferi et al. LEUKEMIA
- The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion
- (2018) Tiziano Barbui et al. Blood Cancer Journal
- Momelotinib therapy for myelofibrosis: a 7-year follow-up
- (2018) Ayalew Tefferi et al. Blood Cancer Journal
- Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
- (2018) Claire N Harrison et al. Lancet Haematology
- Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis
- (2018) John Mascarenhas et al. JAMA Oncology
- SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis
- (2017) Ruben A. Mesa et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis
- (2017) A Pardanani et al. LEUKEMIA
- Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis
- (2017) A Tefferi et al. LEUKEMIA
- Prognostic significance of ASXL1 mutation types and allele burden in myelofibrosis
- (2017) A Tefferi et al. LEUKEMIA
- Low-dose splenic irradiation prior to hematopoietic cell transplantation in hypersplenic patients with myelofibrosis
- (2017) Noah S. Kalman et al. LEUKEMIA & LYMPHOMA
- Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
- (2017) Ruben A Mesa et al. Lancet Haematology
- The prognostic impact of bone marrow fibrosis in primary myelofibrosis
- (2016) Paola Guglielmelli et al. AMERICAN JOURNAL OF HEMATOLOGY
- Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management
- (2016) Mrinal M. Patnaik et al. AMERICAN JOURNAL OF HEMATOLOGY
- Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors
- (2016) Mohamed Shanavas et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- Safety of ruxolitinib therapy prior to allogeneic hematopoietic stem-cell transplantation for myeloproliferative neoplasms
- (2016) A Hanif et al. BONE MARROW TRANSPLANTATION
- Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
- (2016) C N Harrison et al. LEUKEMIA
- Myeloproliferative neoplasms: A decade of discoveries and treatment advances
- (2015) Ayalew Tefferi AMERICAN JOURNAL OF HEMATOLOGY
- Myelodysplastic syndromes: Contemporary review and how we treat
- (2015) Naseema Gangat et al. AMERICAN JOURNAL OF HEMATOLOGY
- Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis
- (2015) N. Kroger et al. BLOOD
- Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition
- (2015) Qiang Jeremy Wen et al. NATURE MEDICINE
- A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis
- (2015) Ayalew Tefferi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
- (2015) Animesh Pardanani et al. JAMA Oncology
- Myeloproliferative Neoplasms
- (2015) Ayalew Tefferi et al. JAMA Oncology
- JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis
- (2014) T Stübig et al. LEUKEMIA
- CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients
- (2014) A Tefferi et al. LEUKEMIA
- The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients
- (2014) P Guglielmelli et al. LEUKEMIA
- Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
- (2013) F. Cervantes et al. BLOOD
- Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?
- (2013) A. Heine et al. BLOOD
- Mutations and prognosis in primary myelofibrosis
- (2013) A M Vannucchi et al. LEUKEMIA
- JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths
- (2012) A. Tefferi BLOOD
- Challenges Facing JAK Inhibitor Therapy for Myeloproliferative Neoplasms
- (2012) Ayalew Tefferi NEW ENGLAND JOURNAL OF MEDICINE
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Transjugular Intrahepatic Porto-Systemic Stent-Shunt for Therapy of Bleeding Esophageal Varices Due to Extramedullary Hematopoiesis in Primary Myelofibrosis: A Case Report
- (2012) Veit Phillip et al. ONKOLOGIE
- Long-term outcome of pomalidomide therapy in myelofibrosis
- (2011) Kebede H. Begna et al. AMERICAN JOURNAL OF HEMATOLOGY
- Indications for and current results with allogeneic hematopoietic cell transplantation in patients with myelofibrosis
- (2011) H. J. Deeg et al. BLOOD
- Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
- (2011) Tiziano Barbui et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis
- (2011) Ayalew Tefferi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Successful treatment of severe extremity pain in myelofibrosis with low-dose single-fraction radiation therapy
- (2010) Michelle A. Neben-Wittich et al. AMERICAN JOURNAL OF HEMATOLOGY
- Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients
- (2010) Alejandra Martínez-Trillos et al. ANNALS OF HEMATOLOGY
- Treatment options for hydroxyurea-refractory disease complications in myeloproliferative neoplasms: JAK2 inhibitors, radiotherapy, splenectomy and transjugular intrahepatic portosystemic shunt
- (2010) Elena Mishchenko et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
- (2010) Naseema Gangat et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- (2010) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prodromal myeloproliferative neoplasms: The 2008 WHO classification
- (2009) Hans Michael Kvasnicka et al. AMERICAN JOURNAL OF HEMATOLOGY
- Outcome of Transplantation for Myelofibrosis
- (2009) Karen K. Ballen et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
- (2009) N. Kroger et al. BLOOD
- A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
- (2009) F. Passamonti et al. BLOOD
- Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level
- (2009) Jocelin Huang et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Lenalidomide Plus Prednisone Results in Durable Clinical, Histopathologic, and Molecular Responses in Patients With Myelofibrosis
- (2009) Alfonso Quintás-Cardama et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started